

On April 8, 2021, Hydro Flask filed a motion for summary determination of a violation of section 337 pursuant to Commission Rules 210.16(c)(2), 210.18 (19 CFR 210.16(c)(2), 210.18) to support its request for entry of a GEO with respect to all asserted patents and trademarks. On August 9, 2021, OUII filed a response in support of the motion.

On September 3, 2021, the presiding chief administrative law judge (“CALJ”) issued an initial determination ("ID") granting in part Hydro Flask’s motion for summary determination. The ID finds that Hydro Flask has shown by reliable, probative, and substantial evidence that a violation of section 337 has occurred with respect to the ‘784, ‘365, and ‘888 trademarks, and the D’468, D’012, and D’320 patents, and that the domestic industry requirement is satisfied for the infringed trademarks and patents. The ID finds that a violation has been established with respect to ten out of thirteen defaulting respondents: Cangnan Kiyisi E-Commerce Technology Co., Ltd.; Yongkang Huiyin Commodity Co., Ltd.; Wuyi Loncin Bottle Co., Ltd.; Zhejiang Yongkang Unique Industry & Trade Co., Ltd.; Suzhou Prime Gifts Co., Ltd.; Hangzhou Yuehua Technology Co., Ltd.; Guangzhou Yawen Technology Co., Ltd.; Shenzhen City Yaxin General Machinery Co., Ltd.; and Shenzhen City Yaxin General Machinery Co., Ltd. The ID also finds that no violation has been established as to respondents Shenzhen Huichengyuan Technology Co., Ltd.; Sinbada Impex Co., Ltd.; and Zhejiang Yuchuan Industry & Trade Co., Ltd.

The ID contains the CALJ’s recommended determination on remedy and bonding (“RD”). The RD recommends issuance of a GEO with respect to the asserted patents and trademarks. The RD does not recommend issuance of any cease and desist orders. No petitions for review were filed.

The Commission determined to review the subject ID in part. See 86 FR 59424–26 (Oct. 27, 2021). Specifically, the Commission determined to review the ID’s finding that Hydro Flask has satisfied the economic prong of the domestic industry requirement under section 337(a)(3)(A). Id.; *see* ID at 89–92. On review, the Commission affirmed the ID’s finding that Hydro Flask has established a domestic industry under section 337(a)(3)(A). Id. The Commission also requested written submissions on remedy, the public interest, and bonding. Id.

On November 4, 2021, Complainants and OUII filed their opening written submissions on remedy, the public interest, and bonding. On November 12, 2021, OUII filed its responsive written submission. No other submissions were received by the Commission.

Having reviewed the submissions filed in response to the Commission request for briefing and the evidentiary record, the Commission has determined that the appropriate form of relief in this investigation is a GEO prohibiting the unlicensed importation of certain vacuum insulated flasks and components thereof that infringe the sole claims of the D’468, D’012, and D’320 patents and the ‘784, ‘365, and ‘888 trademarks.

The Commission has further determined that the public interest factors enumerated in subsection (d)(1) (19 U.S.C. 1337(d)(1)) do not preclude issuance of the above-referenced remedial order. Finally, the Commission has determined that a bond in the amount of one hundred (100) percent of the entered value is required to permit temporary importation of the articles in question during the period of Presidential review (19 U.S.C. 1337(j)). The investigation is terminated.

The Commission’s order and the record upon which it based its determination were delivered to the Secretary to the Commission. The Secretary notified the Secretary of the Treasury of the order.


The Commission vote for this determination took place on January 5, 2022.

By order of the Commission. Issued: January 5, 2022.

Lisa Barton,
Secretary to the Commission.

OUII filed its responsive written submission. The RD does not recommend issuance of any cease and desist orders. No petitions for review were filed.

The Commission determined to review the subject ID in part. See 86 FR 59424–26 (Oct. 27, 2021). Specifically, the Commission determined to review the ID’s finding that Hydro Flask has satisfied the economic prong of the domestic industry requirement under section 337(a)(3)(A). Id.; *see* ID at 89–92. On review, the Commission affirmed the ID’s finding that Hydro Flask has established a domestic industry under section 337(a)(3)(A). Id. The Commission also requested written submissions on remedy, the public interest, and bonding. Id.

On November 4, 2021, Complainants and OUII filed their opening written submissions on remedy, the public interest, and bonding. On November 12, 2021, OUII filed its responsive written submission. No other submissions were received by the Commission.

Having reviewed the submissions filed in response to the Commission request for briefing and the evidentiary record, the Commission has determined that the appropriate form of relief in this investigation is a GEO prohibiting the unlicensed importation of certain vacuum insulated flasks and components thereof that infringe the sole claims of the D’468, D’012, and D’320 patents and the ‘784, ‘365, and ‘888 trademarks.

The Commission has further determined that the public interest factors enumerated in subsection (d)(1) (19 U.S.C. 1337(d)(1)) do not preclude issuance of the above-referenced remedial order. Finally, the Commission has determined that a bond in the amount of one hundred (100) percent of the entered value is required to permit temporary importation of the articles in question during the period of Presidential review (19 U.S.C. 1337(j)). The investigation is terminated.

The Commission’s order and the record upon which it based its determination were delivered to the Secretary to the Commission. The Secretary notified the Secretary of the Treasury of the order.


The Commission vote for this determination took place on January 5, 2022.

By order of the Commission. Issued: January 5, 2022.

Lisa Barton,
Secretary to the Commission.

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**[Docket No. DEA–939]**

**Bulk Manufacturer of Controlled Substances Application: Curia Missouri Inc.**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Curia Missouri Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 14, 2022. Such persons may also file a written request for a hearing on the application on or before March 14, 2022.

** ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on August 19, 2021, Curia Missouri Inc., 2460 West Bennett Street, Springfield, Missouri 65507, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma Hydroxybutyric Acid.</td>
<td>2010</td>
<td>I</td>
</tr>
</tbody>
</table>
## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

**[Docket No. DEA–942]**

**Bulk Manufacturer of Controlled Substances Application: Johnson Matthey, Inc.**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Johnson Matthey, Inc., has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before February 10, 2022. Such persons may also file a written request for a hearing on the application on or before February 10, 2022.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on October 25, 2021, Nexus Pharmaceuticals, Inc., 10300 128th Avenue, Pleasant Prairie, Wisconsin 53158–7338, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled Substance</th>
<th>Drug Code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remifentanil</td>
<td>9739</td>
<td>I</td>
</tr>
</tbody>
</table>

The company plans to import the listed controlled substance for research and analytical testing purposes. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. No other activity for this drug code is authorized for this registration.

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Nexus Pharmaceuticals, Inc. has applied to be registered as an importer of the following basic class(es) of controlled substances:

*Note: The table below lists the controlled substances with their corresponding drug codes and schedules.*

<table>
<thead>
<tr>
<th>Controlled Substance</th>
<th>Drug Code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remifentanil</td>
<td>9739</td>
<td>I</td>
</tr>
</tbody>
</table>

The company plans to import the listed controlled substance for research and analytical testing purposes. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. No other activity for this drug code is authorized for this registration.

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Nexus Pharmaceuticals, Inc. has applied to be registered as an importer of the following basic class(es) of controlled substances:

...